Testing effectiveness (Phase 2)Not Yet RecruitingNCT07110662
What this trial is testing
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Who this might be right for
Toxic Epidermal NecrolysisImmunotherapyCutaneous Adverse Drug Reactions (CADR)
Hospices Civils de Lyon 9